Raymond James Financial
CADL icon

Raymond James Financial’s Candel Therapeutics CADL Stock Holding History

Raymond James Financial’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$432K Buy
41,932
+1,932
+5% +$14.6K ﹤0.01% 4611
2026
Q1 		$196K Buy
40,000
+7,000
+21% +$38.1K ﹤0.01% 4895
2025
Q4 		$186K Buy
33,000
+10,836
+49% +$58.3K ﹤0.01% 4810
2025
Q3 		$113K Hold
22,164
– – ﹤0.01% 4731
2025
Q2 		$112K Sell
22,164
-486
-2% -$2.5K ﹤0.01% 4818
2025
Q1 		$128K Buy
+22,650
New +$185K ﹤0.01% 4509

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Raymond James Financial's CADL Position: Q2 2026 in Review

Raymond James Financial increased its Candel Therapeutics (CADL) stake by 4.8% in Q2 2026, buying an estimated $14.6K and bringing the position to 41,932 shares worth $432K. The position accounts for ﹤0.01% of the portfolio, ranked #4611.

Raymond James Financial first reported a position in CADL in Q1 2025 and has held it in 6 quarters since. 137 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Raymond James Financial held 41,932 shares of Candel Therapeutics worth $432K as of Q2 2026.
  • Raymond James Financial bought 1,932 Candel Therapeutics shares in Q2 2026, an estimated $14.6K.
  • Candel Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #4611 holding.
  • Raymond James Financial first reported a position in Candel Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 137 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.